vs
Side-by-side financial comparison of Gossamer Bio, Inc. (GOSS) and KOPIN CORP (KOPN). Click either name above to swap in a different company.
Gossamer Bio, Inc. is the larger business by last-quarter revenue ($13.8M vs $8.4M, roughly 1.6× KOPIN CORP). KOPIN CORP runs the higher net margin — 81.3% vs -342.3%, a 423.7% gap on every dollar of revenue. On growth, Gossamer Bio, Inc. posted the faster year-over-year revenue change (47.1% vs -42.9%).
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
The Kopin Corporation is a Westborough, Massachusetts-based electronics manufacturer, best known for its microdisplay devices and application specific optical solutions for defense, enterprise, medical and consumer mobile electronics.
GOSS vs KOPN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $8.4M |
| Net Profit | $-47.2M | $6.8M |
| Gross Margin | — | — |
| Operating Margin | -333.6% | -60.0% |
| Net Margin | -342.3% | 81.3% |
| Revenue YoY | 47.1% | -42.9% |
| Net Profit YoY | -43.0% | 449.5% |
| EPS (diluted) | $-0.21 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $8.4M | ||
| Q3 25 | $13.3M | $12.0M | ||
| Q2 25 | — | $8.5M | ||
| Q1 25 | — | $10.5M | ||
| Q4 24 | — | $14.6M | ||
| Q3 24 | — | $13.3M | ||
| Q2 24 | $95.8M | $12.3M | ||
| Q1 24 | $0 | $10.0M |
| Q4 25 | $-47.2M | $6.8M | ||
| Q3 25 | $-48.2M | $4.1M | ||
| Q2 25 | — | $-5.2M | ||
| Q1 25 | — | $-3.1M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | — | $-3.5M | ||
| Q2 24 | $49.2M | $-5.9M | ||
| Q1 24 | $-41.9M | $-32.5M |
| Q4 25 | -333.6% | -60.0% | ||
| Q3 25 | -369.4% | 37.9% | ||
| Q2 25 | — | -64.6% | ||
| Q1 25 | — | -37.1% | ||
| Q4 24 | — | -15.1% | ||
| Q3 24 | — | -21.0% | ||
| Q2 24 | 54.3% | -44.2% | ||
| Q1 24 | — | -325.4% |
| Q4 25 | -342.3% | 81.3% | ||
| Q3 25 | -362.7% | 34.1% | ||
| Q2 25 | — | -61.1% | ||
| Q1 25 | — | -29.5% | ||
| Q4 24 | — | -13.3% | ||
| Q3 24 | — | -26.0% | ||
| Q2 24 | 51.4% | -48.0% | ||
| Q1 24 | — | -324.4% |
| Q4 25 | $-0.21 | $0.04 | ||
| Q3 25 | $-0.21 | $0.02 | ||
| Q2 25 | — | $-0.03 | ||
| Q1 25 | — | $-0.02 | ||
| Q4 24 | — | $0.02 | ||
| Q3 24 | — | $-0.03 | ||
| Q2 24 | $0.22 | $-0.05 | ||
| Q1 24 | $-0.19 | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $136.9M | $36.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-122.8M | $64.1M |
| Total Assets | $172.2M | $108.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $136.9M | $36.4M | ||
| Q3 25 | $180.2M | $26.5M | ||
| Q2 25 | — | $26.8M | ||
| Q1 25 | — | $31.5M | ||
| Q4 24 | — | $35.6M | ||
| Q3 24 | — | $36.2M | ||
| Q2 24 | $354.5M | $17.6M | ||
| Q1 24 | $244.4M | $21.1M |
| Q4 25 | $-122.8M | $64.1M | ||
| Q3 25 | $-82.3M | $21.3M | ||
| Q2 25 | — | $16.0M | ||
| Q1 25 | — | $20.7M | ||
| Q4 24 | — | $23.3M | ||
| Q3 24 | — | $22.7M | ||
| Q2 24 | $81.5M | $-216.3K | ||
| Q1 24 | $26.7M | $4.9M |
| Q4 25 | $172.2M | $108.4M | ||
| Q3 25 | $208.8M | $61.2M | ||
| Q2 25 | — | $61.2M | ||
| Q1 25 | — | $65.0M | ||
| Q4 24 | — | $70.8M | ||
| Q3 24 | — | $70.6M | ||
| Q2 24 | $373.4M | $49.0M | ||
| Q1 24 | $259.4M | $51.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.3M | $-7.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | -1.15× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.3M | $-7.9M | ||
| Q3 25 | $-36.2M | $-110.4K | ||
| Q2 25 | — | $-4.2M | ||
| Q1 25 | — | $-3.4M | ||
| Q4 24 | — | $-1.6M | ||
| Q3 24 | — | $-6.5M | ||
| Q2 24 | $116.3M | $-3.1M | ||
| Q1 24 | $-52.3M | $-3.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-4.9M | ||
| Q1 25 | — | $-3.9M | ||
| Q4 24 | — | $-2.1M | ||
| Q3 24 | — | $-6.5M | ||
| Q2 24 | — | $-3.1M | ||
| Q1 24 | — | $-3.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -57.9% | ||
| Q1 25 | — | -37.1% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | — | -48.6% | ||
| Q2 24 | — | -25.5% | ||
| Q1 24 | — | -33.4% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | 0.0% | 0.5% | ||
| Q1 24 | — | 2.4% |
| Q4 25 | — | -1.15× | ||
| Q3 25 | — | -0.03× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.36× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GOSS
Segment breakdown not available.
KOPN
| Net Product Revenues | $5.6M | 67% |
| Other | $2.7M | 33% |
